On June 16, 2020 OBI Pharma, Inc. (TPEx: 4174), a leader in Glycosphingolipid Immuno-Oncology therapeutics targeting the Globo Series antigens (Globo H and SSEA-4), reported that data highlighting the role of Globo H antigen in cancer survival and its prevalence in different tumor types, will be presented at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II from June 22–24, 2020 (Press release, OBI Pharma, JUN 16, 2020, View Source [SID1234561121]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to share that we have demonstrated Globo H antigens (GH) may play an important role in cancer survival, both in vitro and in vivo. Furthermore, anti-GH antibody treatment can abolish the GH effects and overcome the erlotinib resistance in lung cancer cells in vivo. We are also pleased to share our recent findings on the presence of GH-positive immune cells in the intra- or peri-tumor region using an IHC assay approved by the FDA for investigational use, which suggest GH-ceramide may suppress normal immune functions. The heterogeneous expression of GH among different molecular subtypes of cancer cells may provide a biomarker in the selection of patients for GH-directed therapies," stated Ming-Tain Lai, PhD, Chief Scientific Officer at OBI Pharma.

Session PO ET04.02 Identification of molecular targets 2
Title: The role of Globo H in cancer cell survival
Presenter: Tzer-Min Kuo, PhD, et. al., OBI Pharma, Inc., Taipei, Taiwan
Virtual Meeting II: E-Posters Session: Poster 2934/8
Date/Time: June 22, 2020 from 9:00 AM – 6 PM EST
View Source!/9045/presentation/1616

Session PO ET04.02 Identification of molecular targets 2
Title: The prevalence of Globo H in different tumor types: Breast, pancreatic, lung, gastric, colorectal, liver, and esophageal cancers
Presenter: I-Ju Chen, PhD, et. al., OBI Pharma, Inc. Taipei, Taiwan
Virtual Meeting II: E-Posters Session: Poster 2946/20
Date/Time: June 22, 2020 from 9:00 AM – 6 PM EST
View Source!/9045/presentation/1631

The above poster presentations will be available online at www.obipharma.com on June 22, 2020.